Lubiprostone for treating opioid induced constipation
Status Suspended
Decision Selected
Process STA pre-2018
Topic area
  • Digestive system

Provisional Schedule

Closing date for invited submissions / evidence submission: 28 January 2014
1st appraisal committee meeting: 07 May 2014

Project Team

Communications manager: TBC
Project manager:

Nicole Fisher

Technical Lead: TBC


Key events during the development of the guidance:

Date Update
17 February 2021 This guidance is no longer progressing because Takeda has discontinued lubiprostone (Amitiza).
04 April 2014 7 May 2014 -Committee meeting for this appraisal topic has been cancelled. The appraisal is suspended because the regulatory timeline has changed due to the MHRA not granting a license for this indication. The appraisal topic will be rescheduled into the NICE work programme when the regulatory next steps are known.’

For further information on our processes and methods, please see our CHTE processes and methods manual